<DOC>
	<DOC>NCT00657839</DOC>
	<brief_summary>Assessment of efficacy of vardenafil in the treatment of subjects with symptomatic Benign Prostatic Hyperplasia.The purpose of this study is to find out whether vardenafil can improve the lower urinary tract symptoms of benign prostatic hyperplasia after 8 weeks of daily administration of 10 mg BID.</brief_summary>
	<brief_title>Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Males 45 to 64 years of age Lower urinary tract symptoms &gt; 6 months International Prostate Symptom Score &gt; 12 Prostate Specific Antigen &gt; 3 ng/ml Residual urine volume &gt; 150 m History of myocardial infarction, stroke or lifethreatening arrhythmia within the prior 6 months Nitrate use Other exclusion criteria apply acc. to Summary of Product Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Benign Prostate Hyperplasia</keyword>
	<keyword>Vardenafil</keyword>
	<keyword>Genital Disease</keyword>
	<keyword>Male: Signs and symptoms of Benign Prostate Hyperplasia</keyword>
</DOC>